WO2001087335A2 - Method for selectively inhibiting ghrelin action - Google Patents
Method for selectively inhibiting ghrelin action Download PDFInfo
- Publication number
- WO2001087335A2 WO2001087335A2 PCT/US2001/011752 US0111752W WO0187335A2 WO 2001087335 A2 WO2001087335 A2 WO 2001087335A2 US 0111752 W US0111752 W US 0111752W WO 0187335 A2 WO0187335 A2 WO 0187335A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- ghrelin
- ghs
- compound
- gna
- mixture
- Prior art date
Links
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
- G01N33/5058—Neurological cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/25—Growth hormone-releasing factor [GH-RF] (Somatoliberin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/27—Growth hormone [GH] (Somatotropin)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01K—ANIMAL HUSBANDRY; CARE OF BIRDS, FISHES, INSECTS; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A01K2267/00—Animals characterised by purpose
- A01K2267/03—Animal model, e.g. for test or diseases
- A01K2267/035—Animal model for multifactorial diseases
- A01K2267/0362—Animal model for lipid/glucose metabolism, e.g. obesity, type-2 diabetes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Definitions
- the present invention is in the field of human medicine, particularly in the treatment of obesity and disorders associated with obesity such as diabetes mellitus. More specifically the invention relates to a method for treating obesity by administering a compound which blocks ghrelin action.
- the present invention provides a method of selectively inhibiting ghrelin activity in a mammal comprising administering to a mammal in need thereof a therapeutically-effective amount of a compound selected from the group consisting of a growth hormone secretagogue receptor antagonist (GHS-RA) and a ghrelin neutralizing agent (GNA) .
- the invention further provides a method for treating obesity and related disorders in a mammal comprising administering to a mammal in need thereof a therapeutically-effective amount of a compound selected from the group consisting of a growth hormone secretagogue receptor antagonist (GHS-RA) and a ghrelin neutralizing agent (GNA) .
- Other embodiments include in vi tro and in vivo screening and assay methods .
- GHRH growth hormone-releasing peptides
- GHS-R GHS receptor
- Obesity also called diverence or fatness
- body fat usually caused by the consumption of more calories than the body uses. The excess calories are then stored as fat, or adipose tissue.
- Overweight if moderate, is not necessarily obesity, particularly in muscular or large-boned individuals . In general, however, a body weight 20 percent or more over the optimum tends to be associated with obesity.
- treating or treatment describes the management and care of a patient for the purpose of combating the disease, condition, or disorder.
- Treating includes the administration of a compound of present invention to prevent the onset of the symptoms or complications, alleviating the symptoms or complications, or eliminating the disease, condition, or disorder.
- Treating obesity therefore includes the inhibition of food intake, the inhibition of weight gain, and inducing weight loss in patients in need thereof.
- the term 'related disorders' includes but is not limited to type II diabetes, cardiovascular disease, cancer, and other disease states whose etiology stems from obesity.
- the term 'administering' or 'administration' as used herein includes any means for introducing a GHS-RA or GNA into the body such that the substance is able to interact with the GHS-R or secreted ghrelin.
- Preferred routes of administration will introduce the substance into the systemic circulation. Examples include but are not limited to oral; transdermal; subcutaneous, intravenous, and intramuscular injection.
- the active agents of the present invention are administered to a mammal, preferably a human, in accord with known methods, such as intravenous administration as a bolus or by continuous infusion over a period of time, by intramuscular, intraperitoneal, intracerebral, intracerobrospinal, subcutaneous, intra-articular, intrasynovial, intrathecal, intraocular, intralesional, oral, topical, inhalation or through sustained release.
- a therapeutically-effective amount is at least the minimal dose, but less than a toxic dose, of an active agent which is necessary to impart therapeutic benefit to a mammal. Stated another way, a therapeutically-effective amount is an amount which induces, ameliorates or otherwise causes an improvement in the obese state of the mammal.
- Carriers' as used herein include pharmaceutically- acceptable carriers, excipients, or stabilizers which are nontoxic to the cell or mammal being exposed thereto at the dosages and concentrations employed. Often the physiologically-acceptable carrier is an aqueous pH buffered solution.
- physiologically acceptable carriers include buffers such as phosphate, citrate, and other organic acids; antioxidants including ascorbic acid; low molecule weight (less than about 10 residues) polypeptides; proteins, such as serum albumin, gelatin, or immunoglobulins; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, arginine or lysine; monosaccharides, disaccharides, and other carbohydrates including glucose, mannose, or dextrins; chelating agents such as EDTA; sugar alcohols such as mannitol or sorbitol; salt- forming counterions such as sodium; and/or nonionic surfactants such as TWEEN®, polyethylene glycol (PEG) , and PLURONICS®.
- buffers such as phosphate, citrate, and other organic acids
- antioxidants including ascorbic acid
- low molecule weight (less than about 10 residues) polypeptides proteins, such as serum
- 'mammal' refers to any animal classified as a mammal, including humans, domestic, farm and zoo animals, and sports or companion animals, etc. In a preferred embodiment of the invention, the mammal is a human.
- 'antibody' is used in the broadest sense and specifically includes monoclonal antibodies, chimeric antibodies, humanized antibodies, and fully human antibodies .
- 'monoclonal antibody' refers to an antibody obtained from a population of substantially homogeneous antibodies, i.e., the individual antibodies comprising the population are identical except for possible naturally-occurring mutations that may be present in minor amounts .
- Antibody fragments means a portion of an intact antibody, preferably the antigen binding or variable region of the intact antibody.
- antibody fragments include Fab, Fab', F(ab')l and Fv fragments; diabodies; linear antibodies (Zapata et al . , Protein Engin . S(10): 1057-1 062 (1991)); single-chain antibody molecules; and multispecific antibodies formed from antibody fragments.
- the term 'Fv' is the minimum antibody fragment, which contains a complete antigen-recognition and binding site. This region consists of a dimer of one heavy- and one light chain variable domain in tight, non-covalent association.
- variable domain the three complementarity-determining regions (CDRs) of each variable domain interact to define an antigen-binding site on the surface of the VH-VL dimer.
- CDRs complementarity-determining regions
- the Fab fragment also contains the constant domain of the light chain and the 'first constant domain (CHI) of the heavy chain.
- Fab fragments differ from Fv fragments by the addition of a few residues at the carboxy terminus of the heavy chain CHI domain including one or more cysteines from the antibody hinge region.
- Fab'-SH is the designation herein for Fab' in which the cysteine residue (s) of the constant domains bear a free thiol group.
- F(ab') z antibody fragments originally were produced as pairs of Fab' fragments which have hinge cysteines between them. Other chemical couplings of antibody fragments are also known.
- Papain digestion of antibodies produces two identical antigen-binding fragments, called Fab fragments, each with a single antigen-binding site, and a residual Fc fragment, a designation reflecting the ability to crystallize readily.
- Pepsin treatment yields an F(ab') 2 fragment that has two antigen-combining sites and is still capable of cross- linking antigen.
- immunoglobulins The 'light chains' of antibodies (immunoglobulins) from any vertebrate species can be assigned to one of two clearly distinct types, called kappa and lambda, based on the amino acid sequences of their constant domains .
- immunoglobulins can be assigned to different classes. There are five major classes of immunoglobulins: IgA, IgD, IgE, IgG, and IgM, and several of these may be further divided into subclasses (isotypes) , e.g., IgGl, IgG2, IgG3, IgG4, IgA and IgA2.
- Fv'Single-chain Fv' antibody fragments comprise the VH and VL domains of antibody, wherein these domains are present in a single polypeptide chain.
- the Fv polypeptide further comprises a polypeptide linker between the VH and VL domain, which enables the sFv to form the desired structure for antigen binding.
- the term ' immunoadhesion' designates antibodylike molecules that combine the binding specificity of a heterologous protein (an 'adhesion') with the effector functions of immunoglobulin constant domains.
- the immunoadhesions comprise a fusion of an amino acid sequence with the desired binding specificity which is other than the antigen recognition and binding site of an antibody (i.e., is heterologous), and an immunoglobulin constant domain sequence.
- the adhesion part of an immunoadhesion molecule typically is a contiguous amino acid sequence comprising at least the binding site of a receptor or a ligand.
- the immunoglobulin constant domain sequence in the immunoadhesion may be obtained from any immunoglobulin, such as IgG-1, IgG-2, IgG-3 or IgG-4 subtypes, IgA (including IgG-1 and IgA-2) , IgE, IgD or IgM.
- 'diabodies' refers to small antibody fragments with two antigen-binding sites, which fragments comprise a heavy-chain variable domain (VH) connected to a light chain variable domain (VL) in the same polypeptide chain (VH-VL) .
- VH heavy-chain variable domain
- VL light chain variable domain
- Diabodies are described more fully in, for example, EP 404.097, WO 93/1 1161; and Hollinger et al . , Proc. Natl. Acad. Sci . USA 90: 6444-6448 (1993) .
- a GHS-RA is any compound that partially or fully antagonizes, blocks, or otherwise inhibits the biological action of ghrelin by binding to the GHS-R without stimulating the release of growth hormone. Therefore GHS (compounds that bind the GHS-R and stimulate the release of GH) are not consistent with the claimed method.
- GHS-RA are compounds useful in the presently claimed method and include but are not limited to natural products, synthetic organic compounds, peptides, proteins, antibodies, antibody fragments, single chain antibodies, and antibody based constructs. The current level of skill in the art of receptor binding and growth hormone assays places GHS-RAs well within the grasp of the ordinarily skilled artisan. There are several routine approaches for identifying a GHS-R.
- GHS-RA test compound is first checked to determine if it binds GHS-R. This is accomplished using routine radiometric binding methods .
- a second messenger reporter such as calcium can be used to determine binding.
- Assay is described in Kojima et al . , Nature 402: 656-60 (1999). Compounds that bind GHS-R are then exposed to primary pituitary cells, for example, and release of growth hormone is determined using standard commercially available assays.
- Compounds that bind but do not stimulate the release of GH should then be assayed for ghrelin antagonism by exposing pituitary cells to the GHS-RA in the presence of ghrelin and then assaying for GH release.
- Antibody-based GHS-RAs are also consistent with the claimed method.
- Anti-GHS-R antibodies may be generated by a variety of well-known methods that include traditional antisera production and monoclonal antibody techniques.
- Ghrelin neutralizing agents represent another aspect of the invention.
- ghrelin is neutralized or otherwise rendered biologically inactive apart from the receptor.
- Agents suitable for this application are those which specifically bind ghrelin, preferably with a higher affinity constant than the GHS-R.
- Antibody or antibody-based agents are preferred because they can be purposefully generated using well established techniques.
- Kojima et al . Nature 402: 656-60 (1999) .
- Immunoadhesions Fc fusion constructs, similar to Enbrel®, where the soluble ligand-binding domain of the GHS- R is fused to a human Fc
- Dosages and desired drug concentration of pharmaceutical compositions of the present invention may vary depending on the particular use envisioned. The determination of the appropriate dosage or route of administration is well within the skill of an ordinary artisan. Animal experiments provide reliable guidance for the determination of effective doses for human therapy.
- an article of manufacture containing materials useful in the presently claimed methods comprises a container and a label.
- Suitable containers include, for example, bottles, vials, syringes, and test tubes .
- the containers may be formed from a variety of materials such as glass or plastic.
- the container holds a composition which is effective for specifically inhibiting ghrelin action and may have a sterile access port (for example the container may be an intravenous solution bag or a vial having a stopper pierceable by a hypodermic injection needle) .
- the active agent in the composition is a GHS-RA and/or a GNA.
- the label on, or associated with, the container indicates that the composition is used for treating obesity and/or related disorders.
- the article of manufacture may further comprise a second container comprising a pharmaceutically-acceptable buffer, such as phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial end user standpoint, including other buffers, diluents, filters, needles, syringes, and package inserts with instructions for use.
- Five-minute fractions were collected while monitoring the U.V. at 214 nm (2.0A).
- the appropriate fractions were combined, frozen and lyophilized.
- MALDI- ass spectral analysis indicated a mass of 3313.85 g for the purified ghrelin, which was consistent with the theoretical molecular weight.
- Example 2 Animals Wild-type mice (129SV strain) and NPY-knockout mice were obtained from Taconic Farms ® . Eight-week old dwarf rats were purchased at Harlan UK. Animals were housed individually in a temperature controlled environment (25 C°) with a 12-hour light and 12-hour dark (18.00 - 06.00) photoperiod. All mice had ad libi tum access to pelleted mouse food (5008 PMI ® Nutrition International) and tap water . Mice were between 9 and 13 weeks of age and were injected daily between 17.00 and 18.00 with 0.1 ml of phosphate buffered saline (PBS) containing 0 or 8 mg/kg/d ghrelin over 13 days . Food intake and body weights were measured daily at O ⁇ .OOh. All animal experiments were conducted in accordance with the principles and procedures outlined in the National Institute of Health (NIH) Guide for the Care and Use of Laboratory Animals.
- NASH National Institute of Health
- RQ is the ratio of VC0 2 to V0 2 .
- CV calorific value of oxygen
- Total calories expended were calculated to determine daily fuel utilization.
- proportion of protein, fat and carbohydrate that is utilized during that 24-hour period we used Flatt's proposal and assumed that protein utilization was equivalent to protein intake for adult stable animals (Flatt, J.P., J. Nutr Biochem 2, 193-202 (1991)).
- DXA dual-energy X-ray absorptiometry
- Body composition was measured on day 14 of the treatment period by DXA using a Norland p-DEXA ® (Norland,
- the system provides a non-invasive method for quantification of whole body composition and is based on the differential attenuation of high and low energy x-rays by the tissues in the scan area.
- Soft tissues attenuate the energy beam less than bone; of the soft tissue mass, fat tissue attenuates the beam less than lean tissue.
- Fat mass consists primarily of adipose tissue, but lean mass includes organs, tendons, cartilage, blood and body water in addition to skeletal muscle. In the present study, fat mass, lean mass and bone mineral content (bone mass) were measured and reported. Mice were anesthetized with inhalation of isoflorane and placed on the instrument platform in ventral position. Measurements were performed at a speed of 10 mm/ in and a resolution of 0.5 x 0.5 mm. Quality controls using phantom ID2232 and Calibration Standard 82315 (Norland) were performed before starting measurements .
- Example 5 Example 5
- mice were treated with GHRP-2 for 18 days.
- Hypothalamic RNA levels (measured by RT-PCR) of neuropeptide Y (NPY) , agouti-related-protein (AGRP) , pro- opio-melanocortin (POMC) and melanocyte-concentrating hormone (MCH) were not changed.
- GHRP-6 increases c- fos expression in NPY-neurons (Vernon, R. G.; J Endocrinol 150, 129-40 (1996)) and because these neurons also release AGRP, a natural melanocyte stimulating hormone antagonist
- Recombinant CHO cells expressing the human growth hormone secretagogue receptor cDNA described by Howard et al . , Science 273: 974-977 (1996) are grown and harvested in nutrient medium.
- Membrane preparations are then obtained by first washing the cells with PBS buffer, then twice washing with cold buffer (25 mM HEPES, 2 M MgCl 2 , 1 mM EDTA, 20 ⁇ g/ml Leupeptin, 1 mM PMSF, 2 ⁇ g/ml Aprotinin, 50 ⁇ g/ml Trypsin Inhibitor, pH 8.0) and resuspending in buffer.
- the cell suspension is lysed in a glass Teflon® homogenizer, and the resulting sample is then centrifuged at 35,300 X g for 30 minutes at 4°C.
- the supernatant is removed, and the pellet is resuspended in cold buffer and homogenized. Aliquots may then be prepared and stored at -80°C.
- a sample of the membrane preparation is pre- incubated with a test compound or a control compound with and without added grhelin in buffer (25 mM HEPES, 0.2%
- BSA 2.6 mM Mg, 0.8 mM ATP, 0.1 mM GTP, 5 mM creatine phosphate, creatine kinase 50 U/ml, 0.2 mM IBMX, pH 7.6) is added and incubated for an additional 30 minutes. Incubations are stopped by adding 10 mM EDTA.
- cAMP-b phycoerythrin conjugate is added followed by the addition of affinity purified anti-cAMP rabbit antiserum.
- anti-rabbit IgG coated assay beads are added and incubated for an additional 15 minutes. Plates are then evacuated and read on a Pandex® PFCIA reader.
- ghrelin binding shows decreasing fluorescent intensity due to increased cAMP concentration. Fluorescent intensity values are correlated to rate of cAMP production (pmol/min/mg) . Conversely, inhibition of ghrelin binding by either receptor blockade or ghrelin neutralizations shows no decrease in fluorescent intensity.
- ghrelin is mainly generated by the stomach and secreted into circulation
- total energy 1795 ⁇ 105 kcal
- plasma ghrelin decreased by 30% 2 hours after the meal (p ⁇ 0.01), and over the 24h sampling period (p ⁇ 0.05).
- plasma ghrelin levels did not decrease after meals.
- ghrelin release is a normal response to fasting.
- Such elevated ghrelin stimulates appetite and the utilization of carbohydrate (determined in above examples using rodents) and thus corrects hypoglycemia resulting from fasting.
- Ingestion of glucose rescues hypogylcemia and thus inhibits ghrelin secretion from the stomach to prevent hyperglycemia .
- ghrelin plays an important role in the regulation of blood glucose. Agents that block ghrelin action may be useful for the treatment of diabetes .
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pharmacology & Pharmacy (AREA)
- Pathology (AREA)
- Toxicology (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- General Physics & Mathematics (AREA)
- Organic Chemistry (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Biophysics (AREA)
- Child & Adolescent Psychology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001259056A AU2001259056A1 (en) | 2000-05-17 | 2001-05-07 | Method for selectively inhibiting ghrelin action |
US10/258,259 US20030211967A1 (en) | 2001-05-07 | 2001-05-07 | Method for selectively inhibiting ghrelin action |
EP01932539A EP1286697A2 (en) | 2000-05-17 | 2001-05-07 | Method for selectively inhibiting ghrelin action |
US11/106,899 US20050201938A1 (en) | 2000-05-17 | 2005-04-15 | Method for selectively inhibiting ghrelin action |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20489700P | 2000-05-17 | 2000-05-17 | |
US60/204,897 | 2000-05-17 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/106,899 Continuation US20050201938A1 (en) | 2000-05-17 | 2005-04-15 | Method for selectively inhibiting ghrelin action |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2001087335A2 true WO2001087335A2 (en) | 2001-11-22 |
WO2001087335A3 WO2001087335A3 (en) | 2002-05-16 |
Family
ID=22759933
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/011752 WO2001087335A2 (en) | 2000-05-17 | 2001-05-07 | Method for selectively inhibiting ghrelin action |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP1286697A2 (en) |
AU (1) | AU2001259056A1 (en) |
WO (1) | WO2001087335A2 (en) |
Cited By (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002060472A1 (en) * | 2001-01-31 | 2002-08-08 | Chugai Seiyaku Kabushiki Kaisha | Remedies for hyponutrition status |
WO2002090387A1 (en) * | 2001-05-10 | 2002-11-14 | Queensland University Of Technology | Reproductive cancer diagnosis and therapy |
WO2003051389A3 (en) * | 2001-12-18 | 2003-09-12 | Theratechnologies Inc | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2004004772A1 (en) * | 2002-07-05 | 2004-01-15 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diabetes |
WO2004013274A2 (en) | 2002-08-01 | 2004-02-12 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
WO2004024183A1 (en) * | 2002-09-12 | 2004-03-25 | Pharmexa A/S | Immunization against autologous ghrelin |
US6716629B2 (en) | 2000-10-10 | 2004-04-06 | Biotrove, Inc. | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
WO2004056869A1 (en) * | 2002-12-20 | 2004-07-08 | 7Tm Pharma A/S | Ghrelin receptor inverse agonist for regulation of feeding behaviours |
WO2004084943A1 (en) * | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
WO2005000343A1 (en) * | 2003-06-11 | 2005-01-06 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
WO2005026211A2 (en) * | 2003-09-05 | 2005-03-24 | Eli Lilly And Company | Anti-ghrelin antibodies |
EP1546389A2 (en) * | 2002-09-06 | 2005-06-29 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/igf-1 axis |
WO2005097830A2 (en) * | 2004-04-07 | 2005-10-20 | Aditech Pharma Ab | Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds |
WO2005097831A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of isolated binding members capable of binding specifically to secretagogues |
WO2005113600A2 (en) * | 2004-05-18 | 2005-12-01 | Haptogen Ltd | Methods for the control, treatment and management of obesity |
WO2005114180A2 (en) * | 2004-05-14 | 2005-12-01 | Novo Nordisk A/S | Functional ghs-r antagonists |
WO2006019577A1 (en) * | 2004-07-14 | 2006-02-23 | Eli Lilly And Company | Anti-ghrelin antibodies |
EP1694355A1 (en) * | 2003-10-24 | 2006-08-30 | THE ACADEMIC HOSPITAL ROTTERDAM acting under the name Erasmus MC | Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions |
WO2006091381A1 (en) * | 2005-02-23 | 2006-08-31 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
JP2007513608A (en) * | 2003-11-10 | 2007-05-31 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | Nucleic acids that specifically bind to biologically active ghrelin |
US7252665B2 (en) | 2003-10-31 | 2007-08-07 | Medtronic, Inc | Ablation of stomach lining to reduce stomach acid secretion |
WO2007095347A2 (en) * | 2006-02-13 | 2007-08-23 | The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods and compositions related to ghs-r antagonists |
US7282050B2 (en) | 2003-10-31 | 2007-10-16 | Medtronic, Inc. | Ablation of exterior of stomach to treat obesity |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US7736392B2 (en) | 2005-04-28 | 2010-06-15 | Medtronic, Inc. | Bulking of upper esophageal sphincter for treatment of obesity |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2011053821A1 (en) | 2009-10-30 | 2011-05-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
US8101734B2 (en) | 2005-04-08 | 2012-01-24 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
US8101576B2 (en) | 2006-12-13 | 2012-01-24 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
US8217001B2 (en) | 2001-09-24 | 2012-07-10 | Imperial Innovations Limited | Modification of feeding behavior |
US8222217B2 (en) | 2007-05-31 | 2012-07-17 | Alize Pharma Sas | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
US8318664B2 (en) | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
US8440628B2 (en) * | 2002-05-21 | 2013-05-14 | Daiichi Sankyo Company, Limited | Medical compositions containing ghrelin |
US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
US8992928B2 (en) | 2006-02-11 | 2015-03-31 | Victor Raso | Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin |
WO2015054500A2 (en) | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US9314764B2 (en) | 2000-10-10 | 2016-04-19 | Life Technologies Corporation | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
US9550821B2 (en) | 2011-12-15 | 2017-01-24 | Alize Pharma Sas | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
US10065189B2 (en) | 2004-03-12 | 2018-09-04 | Life Technologies Corporation | Nanoliter array loading |
US10213761B2 (en) | 2004-08-04 | 2019-02-26 | Life Technologies Corporation | Coating process for microfluidic sample arrays |
US10227644B2 (en) | 2000-02-18 | 2019-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for parallel processing of microvolume liquid reactions |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7682565B2 (en) | 2002-12-20 | 2010-03-23 | Biotrove, Inc. | Assay apparatus and method using microfluidic arrays |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021730A1 (en) * | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
WO2000002919A1 (en) * | 1998-07-13 | 2000-01-20 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
WO2000009538A2 (en) * | 1998-08-10 | 2000-02-24 | Merck & Co., Inc. | Canine growth hormone secretagogue receptor |
-
2001
- 2001-05-07 WO PCT/US2001/011752 patent/WO2001087335A2/en active Application Filing
- 2001-05-07 EP EP01932539A patent/EP1286697A2/en not_active Withdrawn
- 2001-05-07 AU AU2001259056A patent/AU2001259056A1/en not_active Abandoned
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997021730A1 (en) * | 1995-12-13 | 1997-06-19 | Merck & Co., Inc. | Growth hormone secretagogue receptor family |
WO2000002919A1 (en) * | 1998-07-13 | 2000-01-20 | Merck & Co., Inc. | Growth hormone secretagogue related receptors and nucleic acids |
WO2000009538A2 (en) * | 1998-08-10 | 2000-02-24 | Merck & Co., Inc. | Canine growth hormone secretagogue receptor |
Non-Patent Citations (2)
Title |
---|
KOJIMA MASAYASU ET AL: "Ghrelin is a growth-hormone-releasing acylated peptide from stomach." NATURE (LONDON), vol. 402, no. 6762, 9 December 1999 (1999-12-09), pages 656-660, XP002187791 ISSN: 0028-0836 cited in the application * |
SMITH R G ET AL: "A nonpeptidyl growth hormone secretagogue." SCIENCE, (1993 JUN 11) 260 (5114) 1640-3. , XP002187790 cited in the application * |
Cited By (111)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10378049B2 (en) | 2000-02-18 | 2019-08-13 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for parallel processing of microvolume liquid reactions |
US10227644B2 (en) | 2000-02-18 | 2019-03-12 | The Board Of Trustees Of The Leland Stanford Junior University | Apparatus and methods for parallel processing of microvolume liquid reactions |
US9314764B2 (en) | 2000-10-10 | 2016-04-19 | Life Technologies Corporation | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
US6716629B2 (en) | 2000-10-10 | 2004-04-06 | Biotrove, Inc. | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
US9968903B2 (en) | 2000-10-10 | 2018-05-15 | Life Technologies Corporation | Apparatus for assay, synthesis and storage, and methods of manufacture, use, and manipulation thereof |
WO2002060472A1 (en) * | 2001-01-31 | 2002-08-08 | Chugai Seiyaku Kabushiki Kaisha | Remedies for hyponutrition status |
WO2002090387A1 (en) * | 2001-05-10 | 2002-11-14 | Queensland University Of Technology | Reproductive cancer diagnosis and therapy |
US8217001B2 (en) | 2001-09-24 | 2012-07-10 | Imperial Innovations Limited | Modification of feeding behavior |
US8071368B2 (en) | 2001-12-18 | 2011-12-06 | Alizé Pharma SAS | Methods for promoting growth and survival of insulin-secreting cells |
US7485620B2 (en) | 2001-12-18 | 2009-02-03 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
WO2003051389A3 (en) * | 2001-12-18 | 2003-09-12 | Theratechnologies Inc | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
US7666833B2 (en) | 2001-12-18 | 2010-02-23 | Alizé Pharma SAS | Pharmaceutical compositions comprising unacylated ghrelin and therapeutical uses thereof |
US8518893B2 (en) | 2002-05-21 | 2013-08-27 | Asubio Pharma Co. Ltd. | Medical compositions containing ghrelin |
US8440628B2 (en) * | 2002-05-21 | 2013-05-14 | Daiichi Sankyo Company, Limited | Medical compositions containing ghrelin |
WO2004002986A2 (en) | 2002-06-28 | 2004-01-08 | Banyu Pharmaceutical Co., Ltd. | Novel benzimidazole derivatives |
WO2004004772A1 (en) * | 2002-07-05 | 2004-01-15 | Chugai Seiyaku Kabushiki Kaisha | Remedy for diabetes |
WO2004013274A2 (en) | 2002-08-01 | 2004-02-12 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
JP2006501864A (en) * | 2002-08-01 | 2006-01-19 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | Ghrelin binding nucleic acid |
WO2004013274A3 (en) * | 2002-08-01 | 2004-05-13 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
US7750140B2 (en) | 2002-08-01 | 2010-07-06 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
EP1546389A4 (en) * | 2002-09-06 | 2006-07-26 | Elixir Pharmaceuticals Inc | Regulation of the growth hormone/igf-1 axis |
EP1546389A2 (en) * | 2002-09-06 | 2005-06-29 | Elixir Pharmaceuticals, Inc. | Regulation of the growth hormone/igf-1 axis |
WO2004024183A1 (en) * | 2002-09-12 | 2004-03-25 | Pharmexa A/S | Immunization against autologous ghrelin |
WO2004056869A1 (en) * | 2002-12-20 | 2004-07-08 | 7Tm Pharma A/S | Ghrelin receptor inverse agonist for regulation of feeding behaviours |
WO2004084943A1 (en) * | 2003-03-19 | 2004-10-07 | Beth Israel Deaconess Medical Center, Inc | Use of antagonists of ghrelin or ghrelin receptor to treat intestinal inflammation |
WO2005000343A1 (en) * | 2003-06-11 | 2005-01-06 | Allergan, Inc. | Use of a clostridial toxin to reduce appetite |
WO2005026211A3 (en) * | 2003-09-05 | 2005-06-16 | Lilly Co Eli | Anti-ghrelin antibodies |
WO2005026211A2 (en) * | 2003-09-05 | 2005-03-24 | Eli Lilly And Company | Anti-ghrelin antibodies |
EP1694355A4 (en) * | 2003-10-24 | 2009-07-29 | Alize Pharma Sas | Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions |
EP1694355A1 (en) * | 2003-10-24 | 2006-08-30 | THE ACADEMIC HOSPITAL ROTTERDAM acting under the name Erasmus MC | Use of ghrelin and unacylated ghrelin compostions in insulin-related disease conditions |
US7825090B2 (en) | 2003-10-24 | 2010-11-02 | Alizé Pharma SAS | Use of ghrelin and unacylated ghrelin compositions for treating insulin resistance |
US7252665B2 (en) | 2003-10-31 | 2007-08-07 | Medtronic, Inc | Ablation of stomach lining to reduce stomach acid secretion |
US7282050B2 (en) | 2003-10-31 | 2007-10-16 | Medtronic, Inc. | Ablation of exterior of stomach to treat obesity |
JP2007513608A (en) * | 2003-11-10 | 2007-05-31 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | Nucleic acids that specifically bind to biologically active ghrelin |
JP4823067B2 (en) * | 2003-11-10 | 2011-11-24 | ノクソン・フアルマ・アクチエンゲゼルシヤフト | Nucleic acids that specifically bind to biologically active ghrelin |
EP2088154A1 (en) | 2004-03-09 | 2009-08-12 | Ironwood Pharmaceuticals, Inc. | Methods and compositions for the treatment of gastrointestinal disorders |
US10974247B2 (en) | 2004-03-12 | 2021-04-13 | Life Technologies Corporation | Nanoliter array loading |
US10065189B2 (en) | 2004-03-12 | 2018-09-04 | Life Technologies Corporation | Nanoliter array loading |
EP2305352A1 (en) | 2004-04-02 | 2011-04-06 | Merck Sharp & Dohme Corp. | 5-alpha-reductase inhibitors for use in the treatment of men with metabolic and anthropometric disorders |
WO2005097830A3 (en) * | 2004-04-07 | 2005-12-22 | Aditech Pharma Ab | Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds |
WO2005097830A2 (en) * | 2004-04-07 | 2005-10-20 | Aditech Pharma Ab | Uses of isolated binding members capable of reducing the biological activity of secretagogue compounds |
WO2005097831A2 (en) * | 2004-04-07 | 2005-10-20 | Gastrotech Pharma A/S | Uses of isolated binding members capable of binding specifically to secretagogues |
WO2005097831A3 (en) * | 2004-04-07 | 2005-12-22 | Gastrotech Pharma As | Uses of isolated binding members capable of binding specifically to secretagogues |
WO2005112903A2 (en) * | 2004-05-14 | 2005-12-01 | Novo Nordisk A/S | Use of ghrelin antagonists for improving cognition and memory |
WO2005114180A2 (en) * | 2004-05-14 | 2005-12-01 | Novo Nordisk A/S | Functional ghs-r antagonists |
WO2005112903A3 (en) * | 2004-05-14 | 2006-02-02 | Novo Nordisk As | Use of ghrelin antagonists for improving cognition and memory |
WO2005114180A3 (en) * | 2004-05-14 | 2006-04-13 | Novo Nordisk As | Functional ghs-r antagonists |
WO2005113600A2 (en) * | 2004-05-18 | 2005-12-01 | Haptogen Ltd | Methods for the control, treatment and management of obesity |
WO2005113600A3 (en) * | 2004-05-18 | 2006-06-08 | Haptogen Ltd | Methods for the control, treatment and management of obesity |
WO2006019577A1 (en) * | 2004-07-14 | 2006-02-23 | Eli Lilly And Company | Anti-ghrelin antibodies |
US11154834B2 (en) | 2004-08-04 | 2021-10-26 | Life Technologies Corporation | Coating process for microfluidic sample arrays |
US10213761B2 (en) | 2004-08-04 | 2019-02-26 | Life Technologies Corporation | Coating process for microfluidic sample arrays |
EP2286837A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and obesity related diseases |
EP2286839A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2286840A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related diseases |
EP2286838A2 (en) | 2004-11-01 | 2011-02-23 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
EP2127676A2 (en) | 2004-11-01 | 2009-12-02 | Amylin Pharmaceuticals, Inc. | Treatment of obesity and related disorders |
WO2006091381A1 (en) * | 2005-02-23 | 2006-08-31 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
US7479271B2 (en) | 2005-02-23 | 2009-01-20 | Eli Lilly And Company | Humanized anti-ghrelin antibodies |
US8101734B2 (en) | 2005-04-08 | 2012-01-24 | Noxxon Pharma Ag | Ghrelin binding nucleic acids |
US7736392B2 (en) | 2005-04-28 | 2010-06-15 | Medtronic, Inc. | Bulking of upper esophageal sphincter for treatment of obesity |
EP2330124A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals Inc. | Hybrid polypeptides with selectable properties |
EP2330125A2 (en) | 2005-08-11 | 2011-06-08 | Amylin Pharmaceuticals, Inc. | Hybrid polypeptides with selectable properties |
WO2007041052A2 (en) | 2005-09-29 | 2007-04-12 | Merck & Co., Inc. | Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators |
US8992928B2 (en) | 2006-02-11 | 2015-03-31 | Victor Raso | Isolated monoclonal antibody or antigen-binding fragment that cleaves octanoylated native ghrelin |
WO2007095347A3 (en) * | 2006-02-13 | 2007-12-21 | Us Gov Health & Human Serv | Methods and compositions related to ghs-r antagonists |
WO2007095347A2 (en) * | 2006-02-13 | 2007-08-23 | The Gov. Of The Usa, As Represented By The Secretary, Dept. Of Health And Human Services | Methods and compositions related to ghs-r antagonists |
EP2946778A1 (en) | 2006-09-22 | 2015-11-25 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
EP2698157A1 (en) | 2006-09-22 | 2014-02-19 | Merck Sharp & Dohme Corp. | Method of treatment using fatty acid synthesis inhibitors |
WO2008060476A2 (en) | 2006-11-15 | 2008-05-22 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US8101576B2 (en) | 2006-12-13 | 2012-01-24 | Imperial Innovations Limited | Compounds and their effects on feeding behaviour |
US8318664B2 (en) | 2007-05-31 | 2012-11-27 | Alize Pharma Sas | Unacylated ghrelin fragments as therapeutic agent in the treatment of obesity |
US8222217B2 (en) | 2007-05-31 | 2012-07-17 | Alize Pharma Sas | Unacylated ghrelin as therapeutic agent in the treatment of metabolic disorders |
EP2998314A1 (en) | 2007-06-04 | 2016-03-23 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
WO2009110510A1 (en) | 2008-03-06 | 2009-09-11 | 萬有製薬株式会社 | Alkylaminopyridine derivative |
EP2810951A2 (en) | 2008-06-04 | 2014-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
US8476408B2 (en) | 2008-06-13 | 2013-07-02 | Alize Pharma Sas | Unacylated ghrelin and analogs as therapeutic agents for vascular remodeling in diabetic patients and treatment of cardiovascular disease |
EP3241839A1 (en) | 2008-07-16 | 2017-11-08 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders |
WO2010047982A1 (en) | 2008-10-22 | 2010-04-29 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010051236A1 (en) | 2008-10-30 | 2010-05-06 | Merck Sharp & Dohme Corp. | Isonicotinamide orexin receptor antagonists |
WO2010051206A1 (en) | 2008-10-31 | 2010-05-06 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2010075068A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Pyridopyrimidine derivatives and methods of use thereof |
WO2010075069A1 (en) | 2008-12-16 | 2010-07-01 | Schering Corporation | Bicyclic pyranone derivatives as nicotinic acid receptor agonists |
WO2011053821A1 (en) | 2009-10-30 | 2011-05-05 | Tranzyme Pharma, Inc. | Macrocyclic ghrelin receptor antagonists and inverse agonists and methods of using the same |
WO2011069038A2 (en) | 2009-12-03 | 2011-06-09 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
WO2011106273A1 (en) | 2010-02-25 | 2011-09-01 | Merck Sharp & Dohme Corp. | Novel cyclic benzimidazole derivatives useful anti-diabetic agents |
WO2012116145A1 (en) | 2011-02-25 | 2012-08-30 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
EP3243385A1 (en) | 2011-02-25 | 2017-11-15 | Merck Sharp & Dohme Corp. | Novel cyclic azabenzimidazole derivatives useful as anti-diabetic agents |
WO2013059222A1 (en) | 2011-10-19 | 2013-04-25 | Merck Sharp & Dohme Corp. | 2-pyridyloxy-4-nitrile orexin receptor antagonists |
US9550821B2 (en) | 2011-12-15 | 2017-01-24 | Alize Pharma Sas | Modulation of ghrelin levels and ghrelin/unacylated ghrelin ratio using unacylated ghrelin |
EP3708179A1 (en) | 2012-03-15 | 2020-09-16 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2013138352A1 (en) | 2012-03-15 | 2013-09-19 | Synergy Pharmaceuticals Inc. | Formulations of guanylate cyclase c agonists and methods of use |
EP4309673A2 (en) | 2012-03-15 | 2024-01-24 | Bausch Health Ireland Limited | Formulations of guanylate cyclase c agonists and methods of use |
WO2014022528A1 (en) | 2012-08-02 | 2014-02-06 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2014130608A1 (en) | 2013-02-22 | 2014-08-28 | Merck Sharp & Dohme Corp. | Antidiabetic bicyclic compounds |
WO2014139388A1 (en) | 2013-03-14 | 2014-09-18 | Merck Sharp & Dohme Corp. | Novel indole derivatives useful as anti-diabetic agents |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
WO2014197720A2 (en) | 2013-06-05 | 2014-12-11 | Synergy Pharmaceuticals, Inc. | Ultra-pure agonists of guanylate cyclase c, method of making and using same |
WO2015051725A1 (en) | 2013-10-08 | 2015-04-16 | Merck Sharp & Dohme Corp. | Antidiabetic tricyclic compounds |
WO2015054500A2 (en) | 2013-10-09 | 2015-04-16 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for downregulation of pro-inflammatory cytokines |
US9708272B2 (en) | 2014-08-29 | 2017-07-18 | Tes Pharma S.R.L. | Inhibitors of α-amino-β-carboxymuconic acid semialdehyde decarboxylase |
WO2016030534A1 (en) | 2014-08-29 | 2016-03-03 | Tes Pharma S.R.L. | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
US10513499B2 (en) | 2014-08-29 | 2019-12-24 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
US11254644B2 (en) | 2014-08-29 | 2022-02-22 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018069532A1 (en) | 2016-10-14 | 2018-04-19 | Tes Pharma S.R.L. | Inhibitors of alpha-amino-beta-carboxymuconic acid semialdehyde decarboxylase |
WO2018106518A1 (en) | 2016-12-06 | 2018-06-14 | Merck Sharp & Dohme Corp. | Antidiabetic heterocyclic compounds |
WO2018118670A1 (en) | 2016-12-20 | 2018-06-28 | Merck Sharp & Dohme Corp. | Antidiabetic spirochroman compounds |
WO2020104456A1 (en) | 2018-11-20 | 2020-05-28 | Tes Pharma S.R.L | INHIBITORS OF α-AMINO-β-CARBOXYMUCONIC ACID SEMIALDEHYDE DECARBOXYLASE |
WO2020167706A1 (en) | 2019-02-13 | 2020-08-20 | Merck Sharp & Dohme Corp. | 5-alkyl pyrrolidine orexin receptor agonists |
WO2021026047A1 (en) | 2019-08-08 | 2021-02-11 | Merck Sharp & Dohme Corp. | Heteroaryl pyrrolidine and piperidine orexin receptor agonists |
WO2022040070A1 (en) | 2020-08-18 | 2022-02-24 | Merck Sharp & Dohme Corp. | Bicycloheptane pyrrolidine orexin receptor agonists |
Also Published As
Publication number | Publication date |
---|---|
EP1286697A2 (en) | 2003-03-05 |
WO2001087335A3 (en) | 2002-05-16 |
AU2001259056A1 (en) | 2001-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050201938A1 (en) | Method for selectively inhibiting ghrelin action | |
WO2001087335A2 (en) | Method for selectively inhibiting ghrelin action | |
Castaneda et al. | Ghrelin in the regulation of body weight and metabolism | |
RU2351359C2 (en) | Application of oxyntomodulin, method and pharmaceutical composition for prevention or treatment of excessive body weight | |
JP6312748B2 (en) | Glycoproteins with lipid mobilization properties and therapeutic uses thereof | |
JP2021185178A (en) | Methods for treatment of bile acid-related disorders | |
BRPI0618160A2 (en) | Alternative complement pathway inhibition for treatment of traumatic brain damage, spinal cord damage and related conditions | |
HU228621B1 (en) | Modification of feeding behavior | |
KR20150104579A (en) | Methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases | |
CN103732618A (en) | Novel oxyntomodulin derivatives and pharmaceutical composition for treating obesity comprising same | |
BR112013033175A2 (en) | peptide sequence, subsequence, composition, pharmaceutical composition, nucleic acid molecule, vector, transformed or host cell, method of treatment for an individual, method for improving glucose metabolism in an individual, and method for identifying a peptide sequence | |
JP2008518941A (en) | Treatment of patients with short bowel syndrome with colorectal continuity | |
AU2016242935A1 (en) | Methods for treating obesity and nonalcoholic fatty liver disease or nonalcoholic steatohepatitis using glucagon receptor antagonistic antibodies | |
US20220340668A1 (en) | Treatment of liver disease or disorder comprising actrii receptor antagonists | |
JP7165495B2 (en) | Motor control function improver | |
US20180340027A1 (en) | Milk fat globule epidermal growth factor 8 regulates fatty acid uptake | |
US20060269550A1 (en) | Anti-ghrelin fab antibodies | |
JP2011506371A (en) | Treatment for pemphigus containing anti-Fas ligand antibody | |
JP5875190B2 (en) | Methylglyoxal-scavenging compounds and their use for the prevention and treatment of pain and / or hyperalgesia | |
CN111905096A (en) | Identification of novel polypeptide hormones for maintaining optimal body weight and blood glucose | |
EP3892289A1 (en) | Pharmaceutical composition, comprising inhibitory peptide against fas signaling, for prevention or treatment of obesity, fatty liver, or steatohepatitis | |
JP2007523196A (en) | Method for treating obesity or diabetes using NT-4 / 5 | |
WO2006114284A2 (en) | AGONISTIC ANTIBODIES THAT BIND TO THE LT-β-RECEPTOR AND THEREBY MODULATE ADIPOSITY-ASSOCIATED PHENOTYPES AS WELL AS THEIR USE IN THERAPY | |
US20240024426A1 (en) | Hypotensive pharmaceutical composition comprising triple activator having activity for all of glucagon, glp-1, and gip receptors | |
CN110177567A (en) | The pharmaceutical composition for the treatment of growth hormone deficiency containing hGH fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
AK | Designated states |
Kind code of ref document: A3 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10258259 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001932539 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2001932539 Country of ref document: EP |
|
NENP | Non-entry into the national phase in: |
Ref country code: JP |